Harmony Biosciences Holdings, Inc. HRMY Stock Appreciation Rights Market Adjustment
Stock Appreciation Rights Market Adjustment at other companies
Other financials
Where this comes from
Reported directly by Harmony Biosciences Holdings, Inc. in its filing.
Tagged under the XBRL concept hrmy:StockAppreciationRightsMarketAdjustment.
The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Harmony Biosciences Holdings, Inc.'s stock appreciation rights market adjustment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Harmony Biosciences Holdings, Inc.'s stock appreciation rights market adjustment?
- Harmony Biosciences Holdings, Inc. (HRMY) reported stock appreciation rights market adjustment of -$312K in Q1 2026.
- How has Harmony Biosciences Holdings, Inc.'s stock appreciation rights market adjustment changed year-over-year?
- Harmony Biosciences Holdings, Inc.'s stock appreciation rights market adjustment decreased by 536.7% year-over-year, from -$49K to -$312K.
- What is the long-term trend for Harmony Biosciences Holdings, Inc.'s stock appreciation rights market adjustment?
- Over 2 years (2021 to 2025), Harmony Biosciences Holdings, Inc.'s stock appreciation rights market adjustment has grown at a -61.8% compound annual growth rate (CAGR), from $446K to $65K.
- What does stock appreciation rights market adjustment mean?
- This represents the non-cash adjustment to the liability associated with stock appreciation rights based on changes in the company's stock price. It reflects the volatility of compensation expenses linked to equity performance rather than operational performance. Investors monitor this to isolate core operating cash flows from market-driven valuation changes.